ArticleBritish journal of cancer2018

Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.

Ádám Póti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.